- Arch Biopartners (ARCH) files new patent application for novel antibody candidates targeting DPEP-1 mediated organ inflammation
- The new patent filing can potentially lead to novel single-domain antibodies or monoclonal antibodies that inhibit DPEP-1 and organ inflammation
- The development of DPEP-1 targeting antibody drugs provides the Arch platform with another class of therapeutics for diseases involving the lungs, kidneys and liver where inflammation plays a prominent role
- The enzyme DPEP-1 was identified for the first time as a major neutrophil adhesion receptor on the lung, liver and kidney endothelium
- Arch Biopartners Inc. (ARCH) is down 2.99 per cent and is trading at C$1.30 at 12:26 pm ET
Arch Biopartners Inc. (ARCH) has filed a provisional patent application with the U.S. Patent and Trademark Office.
The new patent application is to protect new antibody drug candidates that target inflammation in the lungs, liver and kidneys mediated by dipeptidase-1 (DPEP-1).
The new patent filing can potentially lead to novel single domain antibodies or monoclonal antibodies that inhibit DPEP-1 and organ inflammation.
These new antibodies create a third class of drug under development at Arch focused on DPEP-1, alongside the current peptide candidates led by LSALT peptide (Metablok) and the small molecule, cilastatin.
Antibody drugs such as these typically display more specific receptor targeting and longer half-life in the bloodstream compared to peptides or small molecules.
The development of DPEP-1 targeting antibody drugs provides the Arch platform with another class of therapeutics for diseases involving the lungs, kidneys and liver where inflammation plays a prominent role.
“This new class of antibodies that we are developing at Arch Biopartners strengthens our patent portfolio and broadens our drug platform targeting organ inflammation mediated by DPEP-1,” said Richard Muruve, CEO of Arch Biopartners.
Arch Biopartners recently reported the end of patient recruitment for the Phase II trial of LSALT peptide (Metablok).
The trial dosed 61 patients in an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of organ inflammation known to trigger acute respiratory distress syndrome (ARDS) and acute kidney injury in patients infected with SARS-CoV-2 or new variants of the virus.
The composite primary endpoint of the Phase II trial reflects the severe effects often experienced by hospitalized COVID-19 patients and deemed appropriate for LSALT peptide’s novel mechanism of action in blocking consequential inflammation in the lungs, kidneys, and other organs.
The Phase II trial team continues to work on preparing, reconciling and closing the patient data base to enable full analysis of the trial results.
This data management work and closeout of clinical sites continues to progress on schedule with third party data analysis expected to occur during the latter part of July.
The Phase II results will be used to design the Phase III program, including greater patient numbers, to more fully evaluate efficacy and safety in hospitalized patients at risk to inflammation in the lungs, kidneys or liver.
A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019.
In the publication, the enzyme DPEP-1 was identified for the first time as a major neutrophil adhesion receptor on the lung, liver and kidney endothelium.
Their findings identified DPEP-1 as a novel therapeutic target for diseases of these organs where inflammation plays a major role.
Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.
Arch Biopartners Inc. (ARCH) is down 2.99 per cent and is trading at C$1.30 at 12:26 pm ET.
